Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients
Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir (3TC+DTG) could be an effective and tolerated option for simplification in human immunodeficiency virus (HIV)-1-positive patients
ART, Dolutegravir, HIV, Lamivudine, Simplification, Two-drug regimen
Publisher: 'Elsevier BV'
DOI identifier: 10.1016/j.ijantimicag.2019.09.002
Sorry, we are unable to provide the full text but you may find it at the